Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23020812 | 0.86 | TSHR (0.48) | TSHRCYP1A2CYP2C19MAPTHTT | |
| SCHEMBL19354988 | 0.85 | TSHR (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL30637024 | 0.85 | CYP1A2 (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL4134493 | 0.85 | CYP1A2 (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL25317886 | 0.85 | CYP1A2 (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL15805113 | 0.85 | TSHR (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL19354984 | 0.85 | TSHR (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL4135293 | 0.85 | TSHR (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL15797889 | 0.85 | TSHR (0.47) | TSHRCYP1A2CYP2C19MAPTPKM | |
| SCHEMBL4775290 | 0.84 | CA1 (0.52) | TSHRCYP1A2CYP2C19CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016086015-A1 | MYOGLOBIN-BASED CATALYSTS FOR CARBENE TRANSFER REACTIONS | UNIVERSITY OF ROCHESTER (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | TSHR 3799/4885CYP1A2 724/4885CYP2C19 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.